Alzchem Group Ag (ALZCF) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Yeah, good day, ladies and gentlemen, and warm welcome to today's Bionics Call of the Ice Young Group AG, following the publication of the Q1 figures of 2025. I'm delighted to welcome the CEO, Andreas Niedermeyer, CFO, Andreas Ljusler, as well as CSO, Dr. Georg Weichselbaumer, who will speak in a moment and guide us through the presentation and the results. After the presentation, we will move forward with the Q&A session, and with this, let's start. Mr. Niedermayer, the stage is yours. Yes, thank you for the warm introduction. Good morning together. Thank you for joining us today, and welcome to our first quarterly call. For that year, as always, we will go through the presentation first, and then we'll be available for questions at the end. Let's skip the disclaimer and the first slides here. And directly start with the highlights. So the highlights presented here reflect the robust performance of the Alskim Group in quarter one. We are seeing strong development trends in the specialty chemical segment in particular, which made a significant contribution to our sales and EBITDA figures here. So in the area of the free cash flow, we grew disproportionately due to initial customer payments in connection with our capacity expansion for NitroGranitin. The details of this, especially the accounting impact, will be explained to us in more detail later by Mr. Loesler. The Global Scientific Creatine Conference held in Munich in mid-March underscores our commitment to innovation and leadership in the industry. The Creatine Conference became the meeting place for scientists, health and nutrition experts, the trade press, and interested parties who could learn more about the many benefits of creatine. During the four days of the event, there were exciting lectures on the foll...